Press release
Cancer Biomarker Testing Market to Reach US$ 96.53 Billion by 2033, Fueled by Personalized Medicine Revolution
Advancements in AI and Multi-Omics Drive Explosive Growth in Cancer Biomarker TestingAccording to DataM Intelligence, the Global Cancer Biomarker Testing Market surged from US$ 29.83 billion in 2023 to US$ 33.37 billion in 2024, and is projected to reach US$ 96.53 billion by 2033, expanding at a strong CAGR of 12.6% from 2025-2033. The growth stems from the increasing prevalence of cancer globally, rising demand for early detection, and the rapid adoption of personalized medicine supported by AI-powered and multi-omics diagnostic tools.
Get a Free Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/cancer-biomarker-testing-market?utm_source=OpenPR&utm_campaign=Onkar
As diagnostics advance through technologies like liquid biopsy, next-generation sequencing (NGS), and AI-driven analytics, clinicians are now able to detect cancer biomarkers more accurately and cost-effectively. The growing focus on tailored therapy selection and non-invasive real-time monitoring is positioning biomarker testing at the center of modern oncology. North America leads the market due to high R&D investments and robust infrastructure, while Asia-Pacific emerges as the fastest-growing region fueled by expanding healthcare access and oncological research.
Key Highlights from the Report
➤ Global market set to reach US$ 96.53 billion by 2033, growing at 12.6% CAGR.
➤ AI and multi-omics technologies revolutionize early cancer detection and monitoring.
➤ Breast cancer segment leads, representing over US$ 10 billion market value in 2024.
➤ North America holds the largest market share with strong technological leadership.
➤ Increasing R&D in novel biomarkers and liquid biopsy boosts precision oncology.
➤ Rapid expansion across Asia-Pacific driven by cancer care initiatives and awareness.
Market Segmentation
The cancer biomarker testing market is segmented by biomarker type, technology, product type, application, cancer type, end-user, and region.
The breast cancer segment accounted for US$ 10.58 billion in 2024, fueled by the high prevalence of breast cancer and advanced diagnostics targeting biomarkers such as HER2, ER, PR, and Ki-67. Technological innovations like AI-powered pathology, digital PCR assays, and liquid biopsies allow earlier detection and more personalized treatment.
For instance, in December 2024, PathAI introduced the AIM-IHC Breast Panel, enabling precise quantification of critical breast cancer biomarkers. Similarly, in April 2024, Bio-Rad Laboratories launched the ddPLEX ESR1 Mutation Detection Kit, facilitating multiplexed detection of gene mutations related to therapy resistance in breast cancer.
Get Customization in the Report as Per Your Business Requirements: https://www.datamintelligence.com/customize/cancer-biomarker-testing-market?utm_source=OpenPR&utm_campaign=Onkar
Regional Insights
North America Maintains Leadership in Precision Oncology
North America dominates the cancer biomarker testing market, valued at US$ 15.22 billion in 2024, driven by a high cancer prevalence and adoption of advanced tools like NGS and digital pathology. The U.S. remains the epicenter, accounting for US$ 12.20 billion in 2024, with FDA approvals aiding market penetration. In August 2024, Illumina, Inc. received FDA clearance for its TruSight Oncology Comprehensive Test, the first distributable pan-cancer genomic profiling kit.
Similarly, Roche expanded its digital pathology platform in September 2024 by incorporating AI algorithms from multiple partners, enhancing diagnostic speed and accuracy.
Asia-Pacific Emerges as High-Growth Market
Valued at US$ 6.57 billion in 2024, the Asia-Pacific market benefits from increasing cancer incidence and greater investments in medical infrastructure across China, India, and Japan. In April 2025, the LuNGS Alliance and Cancer Research and Statistics Foundation partnered with AstraZeneca, Pfizer, and Roche to provide free NGS biomarker testing for lung cancer patients across India, reflecting growing accessibility and awareness in emerging economies.
Purchase This Exclusive Report at Just USD 4417 Only: https://www.datamintelligence.com/buy-now-page?report=cancer-biomarker-testing-market?utm_source=OpenPR&utm_campaign=Onkar
Market Dynamics
Market Drivers
The integration of AI and multi-omics approaches has greatly improved diagnostic precision, enabling earlier detection and personalized therapies. Collaborative studies such as BioMark Diagnostics' AI-based lung cancer model (2025) underscore how advanced analytics are transforming oncology diagnostics.
Market Restraints
The high costs of biomarker tests and R&D limit accessibility, especially in developing nations. Advanced systems like multiplex assays and NGS require expensive infrastructure and skilled personnel, restricting affordability in low-resource settings.
Market Opportunities
Development of novel biomarkers offers immense potential. New markers like TMB, MSI, and TILs enhance cancer characterization and enable better therapeutic targeting. Collaborations, such as ArteraAI and Tempus (April 2025), are advancing precision oncology by expanding AI-based diagnostic accessibility.
Reasons to Buy the Report
✔ Provides comprehensive analysis of the global cancer biomarker testing landscape.
✔ Identifies technological trends, including multi-omics and AI integration.
✔ Covers detailed market segmentation by cancer type, technology, and region.
✔ Evaluates regional leadership and emerging growth markets.
✔ Offers insight into strategic innovations and key collaborations.
Frequently Asked Questions (FAQs)
◆ How big is the global cancer biomarker testing market?
◆ Which region dominates the cancer biomarker testing industry?
◆ What is the projected CAGR of the market from 2025 to 2033?
◆ Who are the leading players in the cancer biomarker testing market?
◆ What is the market forecast for 2033?
Company Insights
Illumina, Inc.
F. Hoffmann-La Roche Ltd
Thermo Fisher Scientific Inc.
Abbott
QIAGEN
Siemens Healthineers AG
Bio-Rad Laboratories, Inc.
Agilent Technologies
BioMérieux
Foundation Medicine, Inc.
Recent Developments
In May 2025, Cizzle Bio, Inc. partnered with Doctors Hospital (Cayman Islands) to offer blood-based early detection tests for lung and gastric cancers.
In February 2025, Imagene collaborated with Tempus AI, Inc. to advance AI-powered predictive diagnostics for oncology applications.
Conclusion
The global cancer biomarker testing market is rapidly evolving, propelled by technology convergence in AI, genomics, and precision diagnostics. With multi-omics data integration, liquid biopsies, and digital pathology transforming early detection, biomarker testing stands at the forefront of the new era of personalized cancer care. Backed by strong innovation pipelines, expanding healthcare accessibility, and strategic partnerships, the market is poised to triple in value by 2033-reshaping the global oncology diagnostics landscape.
Contact Us
Mr. Sai Kiran
DataM Intelligence 4market Research LLP Ground floor
DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com
Visit Our Website: https://www.datamintelligence.com
About Us
DataM Intelligence 4Market Research is a comprehensive market intelligence platform offering syndicated and customized reports along with expert consulting across multiple industries, including chemicals, healthcare, agriculture, food & beverages, and more. With extensive experience and a strategy-focused approach, DataM provides businesses and individuals with reliable market insights, statistical forecasts, and personalized research solutions to help them make informed decisions and successfully bring innovations to market.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cancer Biomarker Testing Market to Reach US$ 96.53 Billion by 2033, Fueled by Personalized Medicine Revolution here
News-ID: 4215754 • Views: …
More Releases from DataM Intelligence 4Market Research LLP
Regenerative Agriculture Market Set to Reach USD 48.13 Billion by 2032 with 18.2 …
Rising Climate Awareness and Sustainable Initiatives Drive Growth in Regenerative Agriculture
According to DataM Intelligence, the Global Regenerative Agriculture Market reached USD 12,634.54 million in 2024 and is projected to grow significantly, reaching USD 48,139.24 million by 2032 at an impressive CAGR of 18.20% during the forecast period of 2025-2032. The rapid adoption of sustainable farming methods, growing consumer awareness about soil conservation, and climate resilience are the primary factors propelling…
Global Space Robotics Market to Reach USD 10.1 Billion by 2032, Driven by AI Inn …
The Global Space Robotics Market was valued at US$5.2 billion in 2024 and is projected to reach US$10.1 billion by 2032, expanding at a CAGR of 8.7% during the forecast period 2025-2032.
The market focuses on the development and deployment of robotic systems designed for space exploration, satellite servicing, planetary surface operations, and in-orbit manufacturing. Space robotics enhances mission safety, reduces operational costs, and enables long-duration missions beyond human capability.
Rising demand…
United States Multi-Omics Market 2024-2033: Transforming Precision Medicine & Dr …
The Global Multi omics Market reached US$ 3.25 Billion in 2024 and is expected to reach US$ 33.25 Billion by 2033, growing at a CAGR of 26.1% during the forecast period 2025-2033.
The Multi-Omics Market focuses on integrative analysis of genomics, proteomics, metabolomics, and other omics data to understand disease mechanisms and identify biomarkers. Market growth is driven by precision medicine, drug discovery, and personalized healthcare. Advances in high-throughput sequencing, bioinformatics,…
Polyetherimide (PEI) Market Surges with Rising Demand in Aerospace, Automotive & …
The Global Polyetherimide (PEI) Market reached US$ 605.8 million in 2022 and is expected to reach US$ 979.9 million by 2031, growing with a CAGR of 6.2% during the forecast period 2024-2031.
The Polyetherimide (PEI) Market includes high-performance thermoplastics used in aerospace, automotive, electronics, and medical devices. PEI offers heat resistance, dimensional stability, and chemical durability. Market growth is driven by demand for lightweight, high-strength, and flame-retardant materials. Technological advancements in…
More Releases for Bio
Human Plasma Products Market 2023: Industry Future Trends | Takeda, CSL, Grifols …
The Human Plasma Products market research report is proficient and top to bottom research by specialists on the current state of the industry. This statistical surveying report gives the most up to date industry information and industry future patterns, enabling you to distinguish the items and end clients driving income development and benefit. It centres around the real drivers and restrictions for the key players and present challenge status with…
Gene Therapy Products Market | Advantagene, Avalanche Bio, Bluebird Bio, Cellado …
The global gene therapy products market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the gene therapy products market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
Bio-based Polymethyl Methacrylate (Bio-PMMA) Market 2023 | Detailed Report
The Bio-based Polymethyl Methacrylate (Bio-PMMA) report compiles the market information depending upon market development and growth factors, optimizing the growth path. In addition, it highlights the strategies and market share of the leading vendors in the particular market. The report follows a robust research methodology model that helps to make informed decisions. It obtains both qualitative and quantitative market information supported by primary research.
The Bio-based Polymethyl Methacrylate (Bio-PMMA) research report…
Bio Pharma Buffer Market – A comprehensive study by Key Players: Bio-Rad, Lonz …
Latest Market intelligence report released by HTF MI with title "COVID-19 Outbreak-Global Bio Pharma Buffer Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020" is designed covering micro level of analysis by manufacturers and key business segments. The COVID-19 Outbreak-Global Bio Pharma Buffer Market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through primary and secondary…
IVIG Market Anticipated a Noteworthy CAGR during 2019-2024 & Companies Included …
A report added to the rich database of Qurate Business Intelligence, titled “World IVIG Market by Product Type, Players and Regions - Forecast to 2024”, provides a 360-degree overview of the Global market. Approximations associated with the market values over the forecast period are based on empirical research and data collected through both primary and secondary sources. The authentic processes followed to exhibit various aspects of the market makes the…
Green & Bio-based Solvents Market Analysis, Demand, & Opportunities till 2023 | …
A latest research report titled as “Green & Bio-based Solvents Market for Paints & Coatings, Printing Inks, Commercial & Domestic Cleaning, Adhesives & Sealants, Pharmaceutical, Cosmetics, and Other Applications - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023” has been recently added to the vast portfolio of Market Research Reports Search Engine (MRRSE) online research offerings. This report is a professional and in-depth analysis on the…
